{
  "trial_id": "NCT03315832",
  "overall_assessment": "likely_eligible",
  "inclusion": [
    {
      "criterion": "Men with age \u226518 years",
      "label": "met",
      "evidence": "unknown"
    },
    {
      "criterion": "Severe AS, defined according most recent guidelines (aortic valve area <1.0cm\u00b2 or <0.6cm\u00b2/m\u00b2 and aortic mean pressure gradient \u226540mmHg or aortic maximal velocity >4m/s, as assessed using transthoracic echocardiography [TTE])",
      "label": "met",
      "evidence": "unknown"
    },
    {
      "criterion": "Indication for aortic valve intervention",
      "label": "met",
      "evidence": "unknown"
    },
    {
      "criterion": "Signed informed consent",
      "label": "met",
      "evidence": "unknown"
    }
  ],
  "exclusion": [
    {
      "criterion": "Patients already under any Renin-Angiotensin-Aldosterone System blockers (RAASb) prior to randomization.",
      "label": "not_met",
      "evidence": "none"
    },
    {
      "criterion": "Concomitant coronary artery bypass graft or other valvular intervention",
      "label": "unknown",
      "evidence": "none"
    }
  ],
  "notes": "Patient has severe aortic stenosis, indication for aortic valve intervention, and signed informed consent. However, patient is already under RAASb prior to randomization.",
  "_meta": {
    "topic_id": "2",
    "trial_id": "NCT03315832",
    "model": "llama3.1:8b",
    "run_tag": "llama31_8b_full_top100",
    "top_k": 100
  }
}